Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6):681–695.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Richardson PG. CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon. Clin Cancer Res. 2015;21:2660–2662.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470–3478.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Crowell PD, Goldstein AS. Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer. Mol Cell Oncol. 2017;4(2):e1279723.
   PubMed Web of Science ®Google Scholar
• Kotlikoff MI, Kannan MS, Solway J, et al. Methodologic advancements in the study of airway smooth muscle. J Allergy Clin Immunol. 2004;114(2 Suppl):S18–S31.
   PubMedGoogle Scholar
• Horenstein AL, Sizzano F, Lusso R, et al. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med. 2009;15(3–4):76–84.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.
   Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of t regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290–4300.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–2825.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Diels J, Ito T, et al. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol. 2017;92(8):E146–E152.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29:2039–2049.
   PubMed Web of Science ®Google Scholar
• Usmani S, Nahi H, Mateos MV, et al. Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO). Blood. 2016;128(22):1149.
   Web of Science ®Google Scholar
• Chari A, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): pavo, an open-label, multicenter, dose escalation phase 1b study. Blood. 2017;130(1):838.
   Google Scholar
• Martin T, Richter J, Vij R, et al. A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma. Blood. 2015;126(23):509.
   Web of Science ®Google Scholar
• Raab M, Chatterjee M, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma. Blood. 2016;128(22):1152.
   PubMed Web of Science ®Google Scholar
• Van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Spencer A, Hungria VTM, Mateos MV, et al. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor. Blood. 2017;130:3145.
   Web of Science ®Google Scholar
• Mateos MV, Estell J, Barreto W, et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor. Blood. 2016;128:1150.
   Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, White DJ, Benboubker L, et al. Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of pollux. Blood. 2017;30:739.
   Google Scholar
• Moreau P, Kaufman LL, Sutherland HJ, et al. Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure: updated analysis of pollux. Blood. 2016;128:489.
   Google Scholar
• Weisel KC, San Miguel J, Cook G, et al. Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. J Clin Oncol. 2017;35(15 suppl):8006.
   Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay J, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974–981.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mikhael J, Usmani S, et al. Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Blood. 2016;128(22):2123.
   Web of Science ®Google Scholar
• Hofmeister CC, Chari A, Cohen Y, et al. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): centaurus, a randomized, open-label, multicenter phase 2 study. Blood. 2017;130:510.
   Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Cella M, Grierson HL, et al. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517–5521.
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Lai WC, Chuang SS, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Cruz-Munoz M-E, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297–305.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–2840.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–2784.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–138.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–527.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.
   PubMed Web of Science ®Google Scholar
• Richardson P, Wong E, Stockerl-Goldstein K, et al. A phase 2, open-label, multicenter study of Elotuzumab monotherapy in patients with high-risk smoldering multiple myeloma. Haematologica. 2016;101(S1):S815.
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538–548.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Badros AZ, Vredenburgh JJ, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2016;128:976.
   Google Scholar
• Dimopoulos M, Facon T, Richardson P, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). J Clin Oncol. 2012;30(15Suppl):TPS8113.
   Google Scholar
• Takezako N, Ohta K, Handa H, et al. Elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in patients with newly diagnosed multiple myeloma: phase 2, randomized, open-label study in Japan. Blood. 2017;130:434.
   Google Scholar
• Chari A, Mark TM, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Blood. 2016;128:2142.
   Web of Science ®Google Scholar
• Jillella AP, Dainer PM, Kallab AM, et al. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol. 2002;71(3):219–222.
   PubMed Web of Science ®Google Scholar
• Neyer L, Ding H, Chen D, et al. Effect of elotuzumab on circulating lymphocytes, chemokines and cytokines in multiple myeloma patients. Blood. 2010;116:4070.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. EmplicitiTM (elotuzumab) for injection, for intravenous use: US prescribing information. 2015. [cited 2015 Dec 1]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf.
   Google Scholar
• Dimopoulos M, Lonial S, Casado LF, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2015;15:e267–e268.
   Google Scholar
• Caillon H, Irimia A, Simon J, et al. Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test: hydrashift 2/4 Daratumumab. Blood. 2016;128(22):2063.
   Web of Science ®Google Scholar
• Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545–1554.
   PubMed Web of Science ®Google Scholar
• De Vooght KM, Oostendorp M, Van Solinge WW. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing. Curr Opin Hematol. 2016;23:557–562.
   PubMed Web of Science ®Google Scholar
• Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion. 2015;55:2770.
   PubMed Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55:1555–1562.
   PubMed Web of Science ®Google Scholar
• Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51.
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Deep and durable responses in patients (Pts) with relapsed/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against B-cell maturation antigen (BCMA): preliminary results from Part 2 of study BMA117159. Blood. 2017;130:741.
   Web of Science ®Google Scholar
• Sponaas AM, Moharrami NN, Feyzi E, et al. PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLoS One. 2015;10(10):e0139867.
   PubMed Web of Science ®Google Scholar
• Cherkasova E, Espinoza L, Kotecha R, et al. Treatment of ex vivo expanded NK cells with daratumumab F(ab’)2 fragments protects adoptively transferred NK cells from daratumumab-mediated killing and augments daratumumab-induced antibody dependent cellular toxicity (ADCC) of myeloma. Blood. 2015;126(23):4244.
   Web of Science ®Google Scholar
• Casneuf T, Xu X, Adams H, et al. Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma. Haematologica. 2016;B18.
   PubMed Web of Science ®Google Scholar
• Raab M, Goldschmidt H, Agis H, et al. A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). J Clin Oncol. 2015;33(suppl):8574.
   Google Scholar
• Nijhof IS, Casneuf T, Van VJ, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959–970.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje N, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy. Blood. 2017;130:740.
   Web of Science ®Google Scholar
• Mathur R, Zhang Z, He J, et al. Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma. Blood. 2017;130:502.
   Web of Science ®Google Scholar